Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Outrage as NHS watchdog rejects life-prolonging breast cancer drug


A Breast Cancer drug shown to increase the chances of survival for women with the ‘Angelina Jolie gene’ is set to be rejected by the NHS. Studies had shown that olaparib reduced the risk of death by almost a third in women with high-risk, early-stage breast cancer with mutations in the BRCA1 or 2 genes.

A breast cancer drug shown to increase the chances of survival for women with the ‘Jolie gene’ is set to be rejected for use by the NHS.

Studies have shown that olaparib reduces the risk of death by almost a third in women with high-risk, early-stage breast cancer with mutations in the BRCA1 or 2 genes.

But the daily pill was rejected by NICE on the grounds that it is not as cost effective as routine monitoring.

Olaparib, which is taken in tablet form, is already approved as a treatment for some patients with advanced ovarian, breast, prostate and pancreatic cancer.

Experts hailed its approval after trials revealed it was particularly effective against BRCA mutations, exploiting a genetic weakness in cancer cells.

But drugs watchdog NICE said in draft guidelines it would not recommend the treatment for use on the NHS.

Now cancer charities are asking drugmakers AstraZeneca, NICE and NHS England to find a way to prescribe the drug to the hundreds of women who would benefit from it every year.

Baroness Delyth Morgan, chief executive of Breast Cancer Now, said the decision could be a death sentence for some women.

She said: “About 5-10% of women with breast cancer carry an inherited altered gene, of which the BRCA 1 and 2 genes are the most common.

“Unfortunately, some people with high-risk, HER2-negative primary breast cancer with an altered BRCA gene may see their cancer come back after treatment.

“Olaparib has the potential to reduce a patient’s risk of cancer recurring or progressing to incurable secondary breast cancer, and to save people who die from this devastating disease.

“Yet today’s proposed decision robs these patients of the opportunity to receive the best possible treatment and hope for a future without breast cancer.”

The draft guidelines published by NICE said it does not recommend olaparib for adults with high-risk HER2-negative early breast cancer with BRCA1 or 2 mutations who have previously received chemotherapy treatment before or after surgery.

He said the committee appreciated the unmet need for treatment options for these patients and that olaparib was an effective treatment.

Olaparib, which comes in tablet form, is already licensed as a treatment for some patients with advanced ovarian, breast, prostate and pancreatic cancer

However, according to the company’s own analysis, olaparib was not cost-effective compared to routine monitoring, he said.

Andrew Tutt, professor of oncology at King’s College London, said it was a “life-changing drug” for patients diagnosed with this type of hereditary breast cancer at an early stage.

He said: “Today’s decision is a missed opportunity to help more people stay cancer free after treatment, live well and survive breast cancer.”

Kristian Helin, chief executive of the Institute of Cancer Research, London, said: “This is a disappointing decision that will deny people with hereditary breast cancer access to personalized treatment that can improve their survival and help them stay cancer-free in the long term.’

Breast cancer is one of the most common cancers in the world and affects more than two MILLION women a year

Breast cancer is one of the most common cancers in the world. Every year in the UK there are over 55,000 new cases and the disease claims the lives of 11,500 women. In the United States, it strikes 266,000 people each year and kills 40,000. But what causes it and how can it be treated?

What is breast cancer?

Breast cancer starts from a cancerous cell growing in the lining of a duct or lobule in one of the breasts.

When breast cancer has spread to surrounding breast tissue, it is called “invasive” breast cancer. Some people are diagnosed with “carcinoma in situ,” where no cancerous cells have grown beyond the duct or lobule.

Most cases develop in women over 50, but younger women are sometimes affected. Breast cancer can develop in men although it is rare.

Staging means how big the cancer is and whether it has spread. Stage 1 is the earliest stage and stage 4 means the cancer has spread to another part of the body.

Cancer cells are graded from low, which means slow growth, to high, which means fast growth. High-grade cancers are more likely to come back after being treated for the first time.

What causes breast cancer?

A cancerous tumor starts from an abnormal cell. The exact reason why a cell becomes cancerous is unclear. Something is thought to be damaging or altering certain genes in the cell. This makes the cell abnormal and multiplies “out of control”.

Although breast cancer can develop for no apparent reason, certain risk factors can increase the risk of developing breast cancer, such as genetics.

What are the symptoms of breast cancer?

The usual first symptom is a painless lump in the breast, although most breast lumps are non-cancerous and are fluid-filled cysts, which are benign.

The first place where breast cancer usually spreads is the lymph nodes in the armpit. If this happens, you will develop a swelling or lump in an armpit.

How is breast cancer diagnosed?

  • Initial assessment: A doctor examines the breasts and armpits. They can do tests like a mammogram, a special X-ray of the breast tissue that can indicate the possibility of tumors.
  • Biopsy: A biopsy is the removal of a small sample of tissue from a part of the body. The sample is then examined under a microscope to look for abnormal cells. The sample can confirm or rule out cancer.

If you are confirmed to have breast cancer, further tests may be needed to see if it has spread. For example, blood tests, liver ultrasound or chest X-ray.

How is breast cancer treated?

Treatment options that may be considered include surgery, chemotherapy, radiation therapy, and hormone therapy. Often a combination of two or more of these treatments is used.

  • Surgery: Breast-conserving surgery or removal of the affected breast depending on the size of the tumour.
  • Radiation therapy: A treatment that uses high-energy beams of radiation focused on cancerous tissue. This kills cancer cells or stops cancer cells from multiplying. It is mainly used in addition to surgery.
  • Chemotherapy: Treatment of cancer using anticancer drugs that kill cancer cells or prevent them from multiplying
  • Hormone treatments: Some types of breast cancer are affected by estrogen, a “female” hormone, which can stimulate cancer cells to divide and multiply. Treatments that reduce the level of these hormones or prevent them from working are commonly used in people with breast cancer.

How successful is the treatment?

The outlook is better in those who are diagnosed when the cancer is still small and hasn’t spread. Surgical removal of a tumor at an early stage can then give a good chance of recovery.

Routine mammography offered to women aged 50 to 70 means more breast cancers are being diagnosed and treated at an early stage.

For more information visit breastcancercare.org.uk, breastcancernow.org or www.cancerhelp.org.uk

soundhealthandlastingwealth



This post first appeared on انا ايف | AnaEve انا ايف عالمك ا, please read the originial post: here

Share the post

Outrage as NHS watchdog rejects life-prolonging breast cancer drug

×

Subscribe to انا ايف | Anaeve انا ايف عالمك ا

Get updates delivered right to your inbox!

Thank you for your subscription

×